(MarketWatch) Jan 18, 2021 - AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. In the US, gastric cancer is more frequently diagnosed in the advanced stage with only approximately 5% of patients surviving beyond five years.1,2 Approximately one in five gastric cancers are HER2 positive.Read Article
Howard S. Hochster, MD (Posted: January 19, 2021)
Great news for patients with gastric cancer and HER2 overexpression. This ADC of trastuzumab and a topo-1 inhibitor (dexrutecan) prolongs overall survival after FP + trastuzumab first line. It is notable that Daiichi and AZ have conducted this phase 3 trial in gastric cancer so quickly after Breast Cancer approval. Our patients appreciate this excellent option being available!